Dymista: new intranasal rhinitis treatment
The nasal spray Dymista is now available for the treatment of perennial...
News
RSSLyxumia: once-daily injection for type II diabetes
Lyxumia (lixisenatide) is a once-daily parenteral hypoglycaemic for the management of uncontrolled type II diabetes in combination with oral hypoglycaemics and/or insulin.
New Drugs
Lyxumia: once-daily injection for type II diabetes
Lyxumia (lixisenatide) is a once-daily parenteral hypoglycaemic for the management of uncontrolled...
Perjeta: new option for HER2-positive breast cancer
Perjeta (pertuzumab) is licensed for HER2-positive metastatic or locally recurrent unresectable breast...
Zaltrap: new treatment option for metastatic colorectal cancer
Zaltrap (aflibercept) is licensed for the treatment of metastatic colorectal cancer that...
Zoely: combined oral contraceptive containing new progestogen
Zoely is the first combined oral contraceptive to use nomegestrol as its...
Licence Changes & Product Updates
Ixiaro: first Japanese encephalitis vaccine approved for paediatric use in the UK
Children aged 2 months and older can now receive the Japanese encephalitis...
Onglyza approved for triple oral therapy
Onglyza (saxagliptin) can now be used in combination with metformin and a...
Isosorbide mononitrate shortage
The Department of Health has notified healthcare professionals of a supply issue...
Abilify: use in bipolar disorder extended
Abilify is now indicated for the treatment of moderate to severe manic...
Fostair now for maintenance and reliever therapy in asthma
Fostair (formoterol/beclometasone) can now be prescribed for patients with asthma who require...
Guidelines & Clinical Updates
GMC updates prescribing guidance
The General Medical Council (GMC) has published new guidance for all doctors...
Abatacept now approved for rheumatoid arthritis after failure of conventional DMARDs
Following a review, NICE have overturned their previous negative decision for abatacept...
NICE updates guidance and extends use of omalizumab in severe allergic asthma
Omalizumab (Xolair) has been accepted by NICE for broader use in the...
First targeted treatment for idiopathic pulmonary fibrosis approved by NICE
Patients with idiopathic pulmonary fibrosis can now benefit from the novel treatment...
Dopaminergic medication associated with impulse control disorders
Impulse control disorders such as pathological gambling, compulsive shopping or eating, increased...
2-Part CME Diabetes Program
This activity will explore the latest data on the SGLT-2 inhibitors and implications for practice. Click here.
MIMs Drug Search
Possible searches include drugs (by brand, generic ingredient or drug class), diseases and more.
Travel Vaccination & Malaria Advice
Supplied by the National
Travel Health Network
and Centre (NaTHNaC)
